Clinical Trial Update: Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicating that Actinogen Medical's Xanamem (10 mg) is being studied for dementia related to Alzheimer's disease in Phase 2/Phase 3, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• Xanamem

Snippet

Sponsor: Actinogen Medical | Conditions: Dementia Moderate, Dementia, Mild | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING